• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment.

作者信息

Luger Anton

机构信息

Division of Endocrinology and Metabolism, Department of Medicine III, Medical University and General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

出版信息

Endocrine. 2016 Oct;54(1):1-2. doi: 10.1007/s12020-016-1029-z. Epub 2016 Jul 8.

DOI:10.1007/s12020-016-1029-z
PMID:27388591
Abstract
摘要

相似文献

1
Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment.帕西瑞肽治疗肢端肥大症患者的高血糖及其治疗
Endocrine. 2016 Oct;54(1):1-2. doi: 10.1007/s12020-016-1029-z. Epub 2016 Jul 8.
2
Effects of anti-somatostatin agents on glucose metabolism.生长抑素拮抗剂对糖代谢的影响。
Diabetes Metab. 2017 Oct;43(5):411-415. doi: 10.1016/j.diabet.2017.05.003. Epub 2017 Jun 1.
3
Pasireotide in Acromegaly: A Review.《生长激素腺瘤治疗药物：培高利特》述评。
Drugs. 2015 Jun;75(9):1039-48. doi: 10.1007/s40265-015-0413-y.
4
Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.帕西瑞肽治疗肢端肥大症：当前机制与临床数据概述
Neuroendocrinology. 2015;102(1-2):8-17. doi: 10.1159/000381460. Epub 2015 Mar 16.
5
Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.长效帕西瑞肽治疗日本肢端肥大症或垂体巨人症患者的疗效和安全性：一项多中心、开放标签、随机、2期研究的结果
Endocr J. 2017 Jul 28;64(7):735-747. doi: 10.1507/endocrj.EJ16-0624. Epub 2017 Jul 8.
6
Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.对初发活动性肢端肥大症患者，使用帕西瑞肽长效释放制剂联合或不联合奥曲肽长效释放制剂进行术前治疗的系列随访。
J Formos Med Assoc. 2016 Jun;115(6):475-80. doi: 10.1016/j.jfma.2016.02.003. Epub 2016 Apr 23.
7
Pasireotide for the treatment of acromegaly.帕西瑞肽治疗肢端肥大症。
Expert Opin Pharmacother. 2016;17(4):579-88. doi: 10.1517/14656566.2016.1146688. Epub 2016 Feb 17.
8
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.将肢端肥大症患者从奥曲肽转换为帕西瑞肽可改善生化控制：一项随机、双盲、III期研究的交叉扩展
BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8.
9
Pharmacotherapy for acromegaly: future role for pasireotide?肢端肥大症的药物治疗：帕瑞肽的未来作用？
Endocrinol Metab Clin North Am. 2015 Mar;44(1):35-41. doi: 10.1016/j.ecl.2014.10.004. Epub 2014 Nov 4.
10
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.培高利特对比奥曲肽或兰瑞肽治疗未能充分控制的肢端肥大症患者（PAOLA）：一项随机、3 期试验。
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.

引用本文的文献

1
Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.对帕西瑞肽诱导高血糖症中GLP-1和胰岛素分泌机制的深入了解凸显了靶向Gs的糖尿病治疗的有效性。
Sci Rep. 2025 Mar 19;15(1):9494. doi: 10.1038/s41598-025-90896-2.
2
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.库欣综合征、肢端肥大症和神经内分泌肿瘤继发糖尿病的实用治疗方法。
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
3

本文引用的文献

1
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.帕西瑞肽对肢端肥大症控制不佳患者血糖及生长激素相关生物标志物的影响。
Endocrine. 2016 Jul;53(1):210-9. doi: 10.1007/s12020-016-0895-8. Epub 2016 Feb 23.
2
Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.意大利糖尿病研究学会（SID）/意大利内分泌学会（SIE）关于库欣综合征和肢端肥大症高血糖治疗的指南。
J Endocrinol Invest. 2016 Feb;39(2):235-55. doi: 10.1007/s40618-015-0404-6. Epub 2015 Dec 30.
3
Medical treatment of Cushing's disease with concurrent diabetes mellitus.
库欣病合并糖尿病的治疗。
Front Endocrinol (Lausanne). 2023 Apr 17;14:1174119. doi: 10.3389/fendo.2023.1174119. eCollection 2023.
4
Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR.在接受帕西瑞肽长效注射剂治疗的肢端肥大症患者中，胰岛素分泌受损而胰岛素抵抗无变化可解释高血糖现象。
Endocr Connect. 2022 Nov 17;11(12). doi: 10.1530/EC-22-0296. Print 2022 Dec 1.
5
Approach to the Patient With Treatment-resistant Acromegaly.治疗抵抗性肢端肥大症患者的处理方法。
J Clin Endocrinol Metab. 2022 May 17;107(6):1759-1766. doi: 10.1210/clinem/dgac037.
6
The Interaction of Insulin and Pituitary Hormone Syndromes.胰岛素与垂体激素综合征的相互作用。
Front Endocrinol (Lausanne). 2021 Apr 28;12:626427. doi: 10.3389/fendo.2021.626427. eCollection 2021.
7
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant.接受培高利特长效注射剂或培高利特长效注射剂联合聚乙二醇化人生长激素酶促降解重组体治疗的肢端肥大症患者的葡萄糖代谢结局。
Endocrine. 2021 Sep;73(3):658-666. doi: 10.1007/s12020-021-02711-3. Epub 2021 Apr 27.
8
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.帕西瑞肽长效释放制剂治疗肢端肥大症的安全性和耐受性——来自肢端肥大症开放标签、多中心、用于治疗有接受药物治疗需求患者的安全性监测项目（ACCESS）研究的结果
Endocrine. 2017 Jan;55(1):247-255. doi: 10.1007/s12020-016-1182-4. Epub 2016 Nov 28.
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
培高利特对比奥曲肽或兰瑞肽治疗未能充分控制的肢端肥大症患者（PAOLA）：一项随机、3 期试验。
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.
4
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.与帕瑞肽（SOM230）相关的高血糖管理：健康志愿者研究。
Diabetes Res Clin Pract. 2014 Mar;103(3):458-65. doi: 10.1016/j.diabres.2013.12.011. Epub 2013 Dec 25.
5
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.与帕瑞肽相关的高血糖：一项在健康志愿者中进行的机制研究结果。
J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53. doi: 10.1210/jc.2013-1771. Epub 2013 Jun 3.
6
Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.在对生长抑素类似物（SAs）有反应的肢端肥大症患者中，与培维索孟联合治疗。
J Clin Endocrinol Metab. 2011 Aug;96(8):2405-13. doi: 10.1210/jc.2011-0654. Epub 2011 Jun 1.
7
Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.接受手术或生长抑素类似物治疗的肢端肥大症患者的葡萄糖稳态。
Clin Endocrinol (Oxf). 2011 Jul;75(1):96-102. doi: 10.1111/j.1365-2265.2011.03996.x.
8
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.培维索孟与生长抑素类似物（SSA）联合使用对部分抵抗SSA的活动性肢端肥大症非糖尿病患者葡萄糖稳态的长期影响。
Pituitary. 2007;10(3):227-32. doi: 10.1007/s11102-007-0037-7.
9
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.从长效奥曲肽转换为培维索孟治疗的肢端肥大症患者的血糖稳态与安全性
J Clin Endocrinol Metab. 2005 Oct;90(10):5684-91. doi: 10.1210/jc.2005-0331. Epub 2005 Aug 2.
10
Opportunities in somatostatin research: biological, chemical and therapeutic aspects.生长抑素研究的机遇：生物学、化学及治疗学方面
Nat Rev Drug Discov. 2003 Dec;2(12):999-1017. doi: 10.1038/nrd1255.